查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1819942

2025-2033 年肺炎鏈球菌疫苗市場報告（按疫苗類型、產品類型、配銷通路（分銷合作夥伴公司、非政府組織、政府機構）、最終用戶和地區）

Pneumococcal Vaccine Market Report by Vaccine Type, Product Type, Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, Government Authorities), End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球肺炎鏈球菌疫苗市場規模達98億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到149億美元，2025-2033年期間的複合年成長率（CAGR）為4.48%。敗血症和肺炎發病率的上升、人口老化加劇、醫療保健支出的增加、管理機構的舉措和資金投入、監管支持和核准、公共衛生運動以及疫苗技術的進步，共同推動著市場的發展。

肺炎鏈球菌疫苗市場成長因素：

醫療支出不斷上漲

高額的醫療支出使政府和私人醫療機構能夠增加對疫苗接種計畫的投入，從而提高肺炎球菌疫苗的可及性和成本效益，進而提高全民疫苗接種覆蓋率。同時，增加醫療支出往往意味著改善醫療基礎設施，包括疫苗接種診所、分銷網路和訓練有素的醫療專業人員。這些基礎設施有助於肺炎鏈球菌疫苗的管理和宣傳，從而促進市場成長。此外，高額的醫療支出可以促使製藥公司增加對研發活動的投資，從而鼓勵改進肺炎球菌疫苗，使其效果更好、覆蓋更多血清型或需要更少劑量。根據美國醫療保險和醫療補助服務中心網站 2024 年更新的內容，衛生支出預計將佔 GDP 的比重將從 2022 年的 17.3% 增加到 2032 年的 19.7%。

人口老化日益加劇

由於免疫系統較弱和潛在健康問題，老年人更容易感染肺炎球菌，包括肺炎或侵襲性肺炎球菌疾病。這種日益成長的易感性導致人們大量使用肺炎球菌疫苗來避免此類嚴重疾病。此外，許多管理機構和醫療保健組織建議老年人將肺炎球菌疫苗接種納入常規免疫計劃，鼓勵醫療保健提供者和老年人優先接種疫苗，從而推動對肺炎球菌疫苗的需求。此外，醫療保健部門優先考慮針對老齡人口的預防性護理策略，以改善他們的健康狀況並最大限度地減少再入院率。世界衛生組織（WHO）網站上發表的一篇文章顯示，預計到2050年，全球60歲以上人口將加倍，達到近21億。

敗血症盛行率不斷上升

根據世界衛生組織 (WHO) 網站 2024 年更新的內容，全球估計所有敗血症病例中，近 2,000 萬人發生在 5 歲以下兒童。引起肺炎球菌感染的肺炎鏈球菌是敗血症的主要原因之一，尤其是在免疫系統較弱的兒童。肺炎鏈球菌感染引起的敗血症發生率不斷上升，凸顯了疫苗接種等預防措施的重要性。此外，接種肺炎鏈球菌疫苗可顯著降低肺炎球菌感染的風險，包括可能導致敗血症的感染。透過預防肺炎球菌疾病，疫苗有助於減輕醫療機構敗血症的整體負擔。此外，透過預防肺炎球菌疾病，疫苗還可以減輕護理機構敗血症的整體負擔。此外，接種肺炎球菌疫苗作為預防敗血症的保護策略，其銷售量正在成長。全球公共衛生干預中透過疫苗接種來預防敗血症的發病率和死亡率正在支持市場的成長。

肺炎鏈球菌疫苗市場細分：

按疫苗類型分類：

  • 肺炎鏈球菌結合疫苗
  • 肺炎鏈球菌多醣體疫苗

肺炎鏈球菌結合疫苗佔據大部分市場佔有率

肺炎鏈球菌結合疫苗 (PCV) 是市場上最重要的產品之一，因為它能夠有效改善公眾健康，尤其對五歲以下兒童和老年人有益。 PCV 旨在提供各種血清型肺炎鏈球菌的保護，這種細菌已知可導致肺炎、腦膜炎和敗血症等嚴重甚至致命的疾病。 PCV 已被證明可有效降低這些疾病的發生率，因此可以將其納入國家免疫規劃。

按產品類型細分：

  • 上一頁 13
  • 辛弗洛里克斯
  • 肺炎疫苗 23

Prevnar 13 佔據業界最大佔有率

Prevnar 13 因其有效預防肺炎鏈球菌感染而備受青睞。該疫苗尤其以其對13種不同菌株的廣泛覆蓋而聞名。該疫苗被納入全球國家免疫規劃，對肺炎球菌疾病的發生率，尤其是幼兒和老年人群的發生率產生了巨大影響。此外，其成熟的臨床有效性和安全性也確保了其在世界各地的推廣應用，使其成為現代醫療體系對抗肺炎球菌疾病的重要支柱。

按配銷通路細分：

  • 分銷合作公司
  • 非政府組織（NGO）
  • 政府部門

非政府組織（NGO）佔據主要市場佔有率

非政府組織 (NGO) 透過各種措施促進市場活力，包括為疫苗接種計畫提供資金支持、提高人們對肺炎球菌免疫重要性的認知，以及與政府和製藥公司合作，確保疫苗的可負擔性和可及性。非政府組織也參與研發活動，以提高疫苗效力，並推動針對兒童和老年人等弱勢群體的疫苗接種運動。他們的計劃工作也致力於解決醫療保健可近性方面的社會經濟差距，使肺炎球菌疫苗在全球範圍內更容易獲得並產生更大的影響。

按最終用戶分類：

  • 兒科
  • 成年人

兒童，尤其是嬰幼兒，極易感染肺炎球菌，可能導致肺炎、腦膜炎和敗血症等嚴重疾病。因此，全球範圍內建議將肺炎球菌疫苗納入常規兒童免疫接種計劃。肺炎鏈球菌疫苗在預防這些感染方面的有效性顯著降低了全球兒童的發病率和死亡率。此外，針對兒童族群的公共衛生措施和免疫接種計畫也為肺炎球菌疫苗市場統計數據做出了貢獻。

隨著成年人老化，尤其是65歲以上或患有潛在疾病的成年人，他們更容易感染肺炎球菌，這可能導致肺炎、腦膜炎和敗血症等嚴重疾病。成人接種疫苗有助於降低這些感染及其相關併發症的風險，改善整體健康並降低醫療成本。此外，成年人往往是肺炎球菌的攜帶者，可能會將其傳播給兒童和老年人等較脆弱的人。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美領先市場，佔據最大的肺炎球菌疫苗市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是肺炎鏈球菌疫苗最大的區域市場。

根據美國醫療保險和醫療補助服務中心 (Centers for Medicare & Medicaid Services) 網站 2023 年更新的內容，美國醫療保健支出在 2022 年成長了 4.1%，達到 4.5 兆美元，即人均 13,493 美元。醫療保健支出的增加反映出人們更加重視透過創新技術改善患者治療效果並降低整體醫療保健成本。此外，北美擁有嚴格的監管框架和政府對免疫接種計劃的大力支持，這些都對市場的成長做出了重要貢獻。肺炎球菌疾病在北美的流行，加上醫護人員和一般民眾對疫苗接種益處的認知不斷提高，也推動了對肺炎球菌疫苗的需求。

（請注意，這只是關鍵參與者的部分名單，完整名單將在報告中提供。）

  • 主要參與者正在投資研發活動，旨在開發下一代疫苗製劑。他們也在擴大生產能力，以滿足日益成長的全球需求。主要參與者也投資臨床試驗和研究，以證明疫苗的有效性和安全性。他們也正在採用創新技術進行疫苗生產和分銷。許多公司正在進行疫苗接種活動和教育項目，以提高公眾意識和疫苗接種率。主要參與者正在與其他行業利益相關者、政府機構、醫療保健組織和研究機構合作，以擴大市場覆蓋範圍並開發新產品。例如，2023年，Vaxcyte公司與龍沙公司達成了一項新的商業生產協議。透過此次合作，Vaxcyte計劃擴大其PCV候選疫苗的商業生產能力。

本報告回答的關鍵問題

1. 2024年全球肺炎鏈球菌疫苗市場規模？

2. 2025-2033年全球肺炎鏈球菌疫苗市場的預期成長率是多少？

3. COVID-19 對全球肺炎鏈球菌疫苗市場有何影響？

4. 推動全球肺炎鏈球菌疫苗市場發展的關鍵因素有哪些？

5. 根據疫苗類型，全球肺炎鏈球菌疫苗市場是如何分佈的？

6. 根據產品類型，全球肺炎鏈球菌疫苗市場是如何分佈的？

7. 根據配銷通路，全球肺炎鏈球菌疫苗市場如何分佈？

8. 全球肺炎鏈球菌疫苗市場的主要地區有哪些？

9. 全球肺炎鏈球菌疫苗市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球肺炎鏈球菌疫苗市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依疫苗類型

  • 肺炎鏈球菌結合疫苗
  • 肺炎鏈球菌多醣體疫苗

第7章：市場區隔：依產品類型

  • 上一頁 13
  • 辛弗洛里克斯
  • 肺炎疫苗 23

第8章：市場區隔：按配銷通路

  • 分銷合作公司
  • 非政府組織（NGO）
  • 政府部門

第9章：市場區隔：依最終用戶

  • 兒科
  • 成年人

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Astellas Pharma Inc.
    • GlaxoSmithKline Plc.
    • Merck & Co. Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Pvt Ltd.
    • Walvax Biotechnology Co. Ltd.
Product Code: SR112025A3133

The global pneumococcal vaccine market size reached USD 9.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033. The market is driven by the growing occurrence of sepsis and pneumonia diseases, rising aging population, increasing healthcare spending, governing agencies initiatives and funding, regulatory support and approvals, public health campaigns, and advancements in vaccine technology.

Pneumococcal Vaccine Market Growth Factors:

Rising healthcare spending

High healthcare spending allows governments and private healthcare sectors to invest more in vaccination programs, leading to enhanced access and cost-effectiveness of pneumococcal vaccines, thereby increasing vaccination coverage rates across populations. In line with this, increasing healthcare spending often translates into better healthcare infrastructure, including vaccination clinics, distribution networks, and trained healthcare professionals. This infrastructure aids in the management and advocacy for pneumococcal vaccines, thus contributing to the growth of the market. Furthermore, high healthcare spending can lead to an increasing investment in research and development (R&D) activities by pharmaceutical companies, which encourages the enhancement of pneumococcal vaccines that work better, cover more serotypes or need fewer doses. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the health spending share of GDP is forecasted to grow from 17.3 percent in 2022 to 19.7 percent in 2032.

Growing aging population

Older people are more prone to pneumococcal infections, including pneumonia or invasive pneumococcal disease, due to weakened immune systems and underlying health conditions. This increasing vulnerability is leading to high utilization of pneumococcal vaccines to avoid such severe illnesses. Besides this, many governing agencies and healthcare organizations recommend pneumococcal vaccination for elderly populations as part of routine immunization schedules, which encourages healthcare providers and older adults to prioritize vaccination, thereby driving the pneumococcal vaccine demand. In addition, healthcare sectors prioritize preventive care strategies for aging populations to improve their health and minimize hospital readmissions. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 billion worldwide.

Increasing prevalence of sepsis

As per the content updated in 2024 on the website of the World Health Organization (WHO), almost 20 million of all estimated sepsis cases worldwide occurred in children under 5 years of age. Streptococcus pneumoniae, which causes pneumococcal infections, is one of the leading causes of sepsis, especially among children those with weakened immune systems. The rising occurrence of sepsis caused by pneumococcal infections underlines the importance of preventive approaches such as vaccination. In addition, vaccination against Streptococcus pneumoniae significantly reduces the risk of pneumococcal infections, including those that can lead to sepsis. By preventing pneumococcal diseases, vaccines help mitigate the overall burden of sepsis in healthcare settings. Apart from this, they reduce the overall burden of sepsis in care settings by preventing pneumococcal diseases. Furthermore, the administration of pneumococcal vaccines as a protective strategy against sepsis is increasing their sales. Prevention of sepsis morbidity and mortality through vaccination in public health intervention across the globe is supporting the market growth.

Pneumococcal Vaccine Market Segmentation:

Breakup by Vaccine Type:

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

Pneumococcal conjugate vaccine accounts for the majority of the market share

The pneumococcal conjugate vaccine (PCV) is one of the most important products in the market because of its effectiveness in improving public health particularly among children below five years and elderly people. PCVs are aimed at offering protection against various serotypes of the streptococcus pneumoniae bacterium, which is known to cause severe and sometimes fatal conditions such as pneumonia, meningitis, and sepsis. PCVs have been proven to be effective in reducing the incidence of these diseases, which makes it possible to be incorporated in national immunization programs.

Breakup by Product Type:

  • Prevnar 13
  • Synflorix
  • Pneumovax 23

Prevnar 13 holds the largest share of the industry

Prevnar 13 is highly preferable due to its effectiveness in preventing infections caused by Streptococcus pneumoniae bacteria. This vaccine is particularly notable for its broad coverage against thirteen different strains of the bacteria. Its incorporation in national immunization programs worldwide is greatly impacting the cases of pneumococcal diseases especially in young children and older individuals. Moreover, its well-established clinical effectiveness and safety profile are ensuring its escalated utilization throughout the world, making it an essential pillar of modern healthcare systems in combating pneumococcal diseases.

Breakup by Distribution Channel:

  • Distribution Partner Companies
  • Non-Governmental Organizations (NGO)
  • Government Authorities

Non-governmental organizations (NGO) represent the leading market segment

Non-governmental organizations (NGO) contribute to market dynamics through various initiatives, including funding support for vaccination programs, raising awareness about the importance of pneumococcal immunization, and collaborating with governments and pharmaceutical companies to ensure affordability and availability of vaccines. NGOs also engage in R&D activities to improve vaccine efficacy and promote vaccination campaigns aimed at vulnerable populations such as children and the elderly. Their advocacy efforts also address socio-economic disparities in healthcare access, making pneumococcal vaccines more accessible and impactful worldwide.

Breakup by End User:

  • Pediatrics
  • Adults

Children, especially infants and toddlers, are highly vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and sepsis. Vaccination against pneumococcus bacteria is therefore recommended as part of routine childhood immunization schedules worldwide. The effectiveness of pneumococcal vaccines in preventing these infections is significantly reducing morbidity and mortality rates among children globally. Moreover, public health initiatives and immunization programs focused on pediatric populations are contributing to the pneumococcal vaccines market statistics.

As adults are aging, especially those over 65 or with underlying health conditions, they are becoming more vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and septicemia. Vaccination in adults helps reduce the risk of these infections and their associated complications, improving overall health outcomes and reducing healthcare costs. Additionally, adults often serve as carriers of pneumococcal bacteria, potentially spreading it to more vulnerable populations like children and the elderly people.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest pneumococcal vaccine market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pneumococcal vaccine.

As per the content updated in 2023 on the website of Centers for Medicare & Medicaid Services, U.S. health care spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. The increasing healthcare expenditure reflects a greater emphasis on improving patient outcomes and reducing overall healthcare costs through innovative technologies. Moreover, North America has stringent regulatory frameworks and strong government support for immunization programs that contribute significantly to the growth of the market. The prevalence of pneumococcal diseases in North America, coupled with increasing awareness among healthcare professionals and the general population about the benefits of vaccination, is also driving the demand for pneumococcal vaccines.

Competitive Landscape:

  • The market pneumococcal vaccine market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pneumococcal vaccine industry include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd, and Walvax Biotechnology Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players are investing in research and development (R&D) activities aimed at developing next-generation vaccine formulations. They are also expanding manufacturing capabilities to meet the growing global demand. Key players are also investing in clinical trials and studies to demonstrate efficacy and safety. They are also adopting innovative technologies for vaccine production and distribution. Many companies are implementing vaccination campaigns and educational programs to increase awareness and vaccine uptake. Key players are collaborating with other industry stakeholders, government agencies, healthcare organizations, and research institutions to expand their market reach and develop new products. For instance, in 2023, Vaxcyte, Inc. collaborated with Lonza for a new commercial manufacturing agreement. With this collaboration, Vaxcyte planned to expand its commercial manufacturing capacity for its PCV candidates.

Key Questions Answered in This Report

1. What was the size of the global pneumococcal vaccine market in 2024?

2. What is the expected growth rate of the global pneumococcal vaccine market during 2025-2033?

3. What has been the impact of COVID-19 on the global pneumococcal vaccine market?

4. What are the key factors driving the global pneumococcal vaccine market?

5. What is the breakup of the global pneumococcal vaccine market based on the vaccine type?

6. What is the breakup of the global pneumococcal vaccine market based on the product type?

7. What is the breakup of the global pneumococcal vaccine market based on the distribution channel?

8. What are the key regions in the global pneumococcal vaccine market?

9. Who are the key players/companies in the global pneumococcal vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pneumococcal Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Pneumococcal Conjugate Vaccine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pneumococcal Polysaccharide Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Prevnar 13
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Synflorix
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Pneumovax 23
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Distribution Partner Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-Governmental Organizations (NGO)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Government Authorities
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Astellas Pharma Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 GlaxoSmithKline Plc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Merck & Co. Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Panacea Biotec Ltd.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Pfizer Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Sanofi S.A.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Serum Institute of India Pvt Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Walvax Biotechnology Co. Ltd.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials

List of Figures

  • Figure 1: Global: Pneumococcal Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Pneumococcal Vaccine Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pneumococcal Vaccine Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Pneumococcal Vaccine Market: Breakup by Vaccine Type (in %), 2024
  • Figure 5: Global: Pneumococcal Vaccine Market: Breakup by Product Type (in %), 2024
  • Figure 6: Global: Pneumococcal Vaccine Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Pneumococcal Vaccine Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Pneumococcal Vaccine Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Pneumococcal Vaccine (Prevnar 13) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Pneumococcal Vaccine (Prevnar 13) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Pneumococcal Vaccine (Synflorix) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Pneumococcal Vaccine (Synflorix) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Pneumococcal Vaccine (Pneumovax 23) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Pneumococcal Vaccine (Pneumovax 23) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Pneumococcal Vaccine (Government Authorities) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Pneumococcal Vaccine (Government Authorities) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Pneumococcal Vaccine (Pediatrics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Pneumococcal Vaccine (Pediatrics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Pneumococcal Vaccine (Adults) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Pneumococcal Vaccine (Adults) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia-Pacific: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia-Pacific: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Middle East and Africa: Pneumococcal Vaccine Market: Breakup by Country (in %), 2024
  • Figure 78: Global: Pneumococcal Vaccine Industry: SWOT Analysis
  • Figure 79: Global: Pneumococcal Vaccine Industry: Value Chain Analysis
  • Figure 80: Global: Pneumococcal Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pneumococcal Vaccine Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pneumococcal Vaccine Market Forecast: Breakup by Vaccine Type (in Million USD), 2025-2033
  • Table 3: Global: Pneumococcal Vaccine Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 4: Global: Pneumococcal Vaccine Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Pneumococcal Vaccine Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Pneumococcal Vaccine Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Pneumococcal Vaccine Market: Competitive Structure
  • Table 8: Global: Pneumococcal Vaccine Market: Key Players